ISMRD would like to congratulate JCR Pharmaceuticals for its WORLDSymposium™ 2022 New Treatment Award.  The award will be presented to JCR Pharmaceuticals  for pabinafusp alfa (IZCARGO®), which provided clinical data meriting approval by the Ministry of Health, Labour and Welfare in Japan.  Pabinafusp alfa is the first approved Enzyme Replacement Therapy for MPS II (Hunter Syndrome) to penetrate the Blood-Brain Barrier via intravenous administration. This is an important achievement in therapy for lysosomal diseases for attaining regulatory approval.

The New Treatment Award will be presented to JCR Pharmaceuticals on Thursday, February 10, 2022, at the  18th Annual WORLDSymposium™ 2022 in San Diego.

Well done, JCR Pharmaceuticals